OR

Ortin Laboratories LtdNSE ORTINLAB Stock Report

Last reporting period 31 Mar, 2024

Updated 14 Nov, 2024

Last price

Market cap $B

0.004

Micro

Exchange

XNSE - National Stock Exchange Of India

ORTINLAB.NS Stock Analysis

OR

Uncovered

Ortin Laboratories Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-55/100

Low score

Market cap $B

0.004

Dividend yield

Shares outstanding

8.131 B

Ortin Laboratories Ltd. engages in the manufacture of drug intermediates and pharmaceuticals products. The company is headquartered in Hyderabad, Telangana. The company manufactures a range of pharmaceutical formulations of tablets, capsules, syrups, and dry powders. The firm's products include Acefinac, ACEFINAC-CZ, ACEFINAC-P, ACEFINAC-SP, ACTAZID, ACTY-P, ALERFEX-120, ALERFEX-180, ALERGID, ALERGID- L, AMLOBID, CARBAMOL, CARISNIL, CALDY-C AZITIN-500, DOCEF-200, GLYCITROL, GLYCITROL-M, LORACT, MEBOL, NEUROCOB, FERUP, IRFER Z, MINVITA-B, NILCID, ORICILLIN-DX, PEG POWDER, PEG-D POWDER, ALKASIT, COF-XL, DECODIL, ENCENIL and OROMOX DRY SYRUP. Its formulations include Anti Diabetics, Anti Allergics, Anti Anginal and Cardiovascular, Analgesics and Antipyretics, and Anti Biotics-Quinolones. Its active pharmaceutical ingredient (API) intermediates include Anti retro viral, Grignard, Diborane, Ciprofloxacin and Tramadol. The company is also manufacturing for different importers to market their products in Russia, Ukraine, Kajakistan and South America.

View Section: Eyestock Rating